R Latini

Summary

Affiliation: Istituto di Ricerche Farmacologiche Mario Negri
Country: Italy

Publications

  1. pmc Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial
    Marcello Disertori
    Department of Cardiology, Santa Chiara Hospital, Trento, Italy
    BMC Cardiovasc Disord 13:28. 2013
  2. ncbi request reprint Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy
    Eur J Heart Fail 14:992-9. 2012
  3. doi request reprint Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milan Istituti Ospitalieri, Cremona POL Madonna della Consolazione, Reggio Calabria, Italy
    J Intern Med 269:160-71. 2011
  4. ncbi request reprint Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    J Am Coll Cardiol 35:1801-7. 2000
  5. ncbi request reprint Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial
    R Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, 62 20157 Milan, Italy
    Heart Dis 2:185-90. 2000
  6. doi request reprint High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals
    S Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Intern Med 273:306-17. 2013
  7. ncbi request reprint Left ventricular response to beta-adrenergic stimulation in aging rats
    S Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Gerontol A Biol Sci Med Sci 55:B35-41; discussion B42-3. 2000
  8. ncbi request reprint Cardiac protection by pharmacological modulation of inflammation
    R Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    Expert Opin Investig Drugs 10:1913-24. 2001

Detail Information

Publications8

  1. pmc Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial
    Marcello Disertori
    Department of Cardiology, Santa Chiara Hospital, Trento, Italy
    BMC Cardiovasc Disord 13:28. 2013
    ..Few data on the thromboembolic (TE) risk of paroxysmal and persistent atrial fibrillation (AF) are available. This study aimed to assess the incidence of TE events in paroxysmal and persistent AF...
  2. ncbi request reprint Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy
    Eur J Heart Fail 14:992-9. 2012
    ..Since the role of inflammation in the progression of chronic heart failure (HF) is debated, we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF...
  3. doi request reprint Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milan Istituti Ospitalieri, Cremona POL Madonna della Consolazione, Reggio Calabria, Italy
    J Intern Med 269:160-71. 2011
    ..we evaluated the prognostic role of circulating cardiovascular biomarkers in patients with a history of recent atrial fibrillation (AF)...
  4. ncbi request reprint Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting
    R Latini
    Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    J Am Coll Cardiol 35:1801-7. 2000
    ..We sought to determine whether the clinical effects of early angiotensin-converting enzyme (ACE) inhibitor (ACEi) treatment for acute myocardial infarction (MI) are influenced by the concomitant use of aspirin (ASA)...
  5. ncbi request reprint Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial
    R Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea, 62 20157 Milan, Italy
    Heart Dis 2:185-90. 2000
    ..Lisinopril is safe and effective when given early after the onset of myocardial infarction, regardless of a concomitant administration of ASA started early and continued over a 6-week period...
  6. doi request reprint High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals
    S Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Intern Med 273:306-17. 2013
    ..To investigate the association between circulating cardiac biomarkers and minor abnormalities in cardiac phenotype [left ventricular (LV) mass and midwall fractional shortening (MFS)] in elderly individuals in a general population sample...
  7. ncbi request reprint Left ventricular response to beta-adrenergic stimulation in aging rats
    S Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Gerontol A Biol Sci Med Sci 55:B35-41; discussion B42-3. 2000
    ....
  8. ncbi request reprint Cardiac protection by pharmacological modulation of inflammation
    R Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    Expert Opin Investig Drugs 10:1913-24. 2001
    ..Similarly, results of trials aimed at preventing cardiovascular events by eradicating chronic infections will be among the first to directly test whether such therapies will decrease risks of cardiovascular disease...